ImmunoGen Inc (IMGN)

[XenaLives]

Sounds good..

FINANCIAL GUIDANCE

Following the completion of its operational review in June 2019, ImmunoGen has updated its financial guidance for 2019 as follows:

- revenues between $40 million and $45 million;
- operating expenses between $175 million and $180 million; and
- cash and cash equivalents at December 31, 2019, between $165 million and $170 million.

ImmunoGen expects that its current cash, together with expense reductions resulting from the operational changes previously announced and anticipated cash receipts from partners, will fund operations through the release of top-line results from the upcoming mirvetuximab Phase 3 study in platinum-resistant ovarian cancer, which are expected in the first half of 2022.

https://finance.yahoo.com/news/immunogen-reports-recent-progress-second-103000972.html?.tsrc=rss